Poster Presentations

Posters will be on display digitally throughout the congress.
A moderated poster session will take place on Friday, September 12, 2025 from 17:50 to 19:00.

Poster presentations will take place at the station mentioned below:

Group (screen) 1:

Chairpersons:
Mauricio Leon, Lima Peru
Bruce Mann, Melbourne, Australia

Adjuvant endocrine therapy

17:50
RIBOCICLIB IN HR+/HER2− ADVANCED BREAST CANCER: A REAL-WORLD STUDY FROM A PUBLIC HOSPITAL IN SOUTHERN PERU
Livia Lucila Martinez Ocola, Peru

Breast cancer genetic

17:55
STREAMLINED PATHWAYS TO EMBED GENETIC TESTING INTO EXISTING BREAST CANCER MDT
Lynne Mann, Australia

Breast imaging

18:00
VALUE OF A MACHINE LEARNING MODEL COMBINING CLINICAL FEATURES AND MULTIPARAMETRIC MRI IN PREDICTING BENIGN AND MALIGNANT CHARACTERISTICS OF BI-RADS 4 LESIONS
Jiangyong Shi, China

Molecular assays

18:05
REAL-WORLD VALIDATION OF ONCOTYPE DX® IN NODE NEGATIVE BREAST CANCER: A COMPARATIVE ANALYSIS WITH TAILORX
Ryan Rodgerson, United Kingdom

18:10
IS THE ONCOTYPE DX® VALIDATED FOR REAL-WORLD USE IN NODE-POSITIVE BREAST CANCER? A RETROSPECTIVE COHORT STUDY
Ryan Rodgerson, United Kingdom

Neoadjuvant therapy

18:15
NEOADJUVANT THERAPY FOR BREAST CANCER: A REGIONAL AUSTRALIAN EXPERIENCE
Ruwangi Udayasiri, Australia

18:20
COMPARISON OF THE EFFICACY OF SENTINEL LYMPH NODE BIOPSY AND AXILLARY LYMPH NODE DISSECTION IN BREAST CANCER PATIENTS AFTER NEOADJUVANT THERAPY
Meiling Xu, China

Precision oncology

18:25
ASSESSING THE BIOMARKER POTENTIAL OF A PANEL OF MICRORNA IN LUMINAL A AND B BREAST CANCER IN A PERUVIAN POPULATION
Carla Bernal Espinoza, Peru

18:30
METABOLOMIC ANALYSIS OF BREAST CANCER IN COLOMBIAN PATIENTS: EXPLORING MOLECULAR SIGNATURES IN DIFFERENT SUBTYPES AND STAGES
Andrea Del Pilar Hernandez Rodriguez, Colombia

18:35
BREAST TISSUE NANOMECHANICS SIGNATURE AIDS ACCURATE BREAST CANCER DIAGNOSIS AND SUPPORTS BETTER-INFORMED TREATMENT DECISIONS
Carolina Ortiz Velez, Switzerland

18:40
LOW IMPACT BREAST RECONSTRUCTION (LIBRRE): A MULTI CENTRIC ANALYSIS OF 900 PATIENTS UNDERGOING DELAYED AUTOLOGOUS FAT GRAFTING
Kais Razzouk, France

 

Group (screen) 2:

Chairpersons:
Luis Pinillos, Lima, Peru
Richard de Boer, Melbourne, Australia

Prevention

17:50
CONTRAST-ENHANCED MAMMOGRAPHY ENHANCED WITH ARTIFICIAL INTELLIGENCE FOR BREAST CANCER PREDICTION: A SYSTEMATIC REVIEW WITH EVALUATION PROBAST
Wagner Rios-Garcia, Peru

17:55
DECREASED RISK OF BREAST CANCER ASSOCIATED WITH METFORMIN TREATMENT
Jose Richard Tenazoa Villallobos, Peru

18:00
PROGNOSTIC FACTOR ASSOCIATED WITH RECURRENCE IN MALIGNANT PHYLLODES TUMOR: RETROSPECTIVE COHORT OF CASES TREATED AT THE INSTITUTE OF NEOPLASTIC DISEASES PERIOD 2000-2020ª
Jose Richard Tenazoa Villallobos, Peru

Screening

18:05
COMPARISON OF CLINICAL BREAST EXAM AND BEXA BREAST EXAM FOR DETECTION OF BREAST ABNORMALITIES IN COLOMBIAN WOMEN AGED 40–49 YEARS
Steffi Katheryn Gonzales, Peru

18:10
EXPLORATION OF SERUM METABOLITES ASSOCIATED WITH MAMMOGRAPHIC DENSITY AS A RISK FACTOR FOR BREAST CANCER
Gabriela Lopez Molina, Colombia

18:15
USE OF ARTIFICIAL INTELLIGENCE FOR BREAST CANCER SCREENING IN LATIN AMERICA AND THE CARIBBEAN: A SYSTEMATIC REVIEW WITH TRIPOD-AI EVALUATION
Wagner Rios-Garcia, Peru

Symptom management

18:20
OUR EXPERIENCE WITH LOCALIZING SENTINEL LYMPH NODES VIA MAGTRACE (SPIO) COMPARED TO CONVENTIONAL METHODS, INCLUDING TECHNETIUM-99M (TC-99M) AND BLUE DYE (BD)METHODS, FOR METASTATIC BREAST CANCER
Maryam Barkat, United Kingdom

Triple negative breast cancer

18:25
PROGNOSTIC FACTORS ASSOCIATED WITH AXILLARY RECURRENCE WITH SENTINEL NODE-NEGATIVE BIOPSY IN BREAST CANCER T1 – T2, N0
Jose Richard Tenazoa Villallobos, Peru

DCIS

18:30
RISK FACTORS FOR RECURRENCE OF NON-METASTATIC DUCTAL CARCINOMA OF THE BREAST
Jose Richard Tenazoa Villallobos, Peru

Locoregional therapy

18:35
ASSOCIATION BETWEEN THE NOTTINGHAM PROGNOSTIC INDEX AND 5-YEAR ACTUARIAL SURVIVAL IN BREAST CANCER LUMINAL A. VIRGEN DE LA PUERTA HIGH COMPLEXITY HOSPITAL 2019-2022
Jose Richard Tenazoa Villallobos, Peru

18:40
COSMETIC OUTCOMES WITH THREE HYPOFRACTIONATED ADJUVANT RADIOTHERAPY SCHEDULES IN PATIENTS WITH BREAST CANCER
Budhi Singh Yadav, India

Skip to content